Health

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…

5 days ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

February 11, 2026 06:00 ET  | Source: Upstream Bio – Verekitug provided statistically significant and clinically meaningful reductions in annualized…

6 days ago

Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed…

6 days ago

AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences

DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the…

6 days ago

BioAro Secures UAE Approval for AI-Enabled Longevity Bioactives, Setting the Stage for Global Expansion

DUBAI, United Arab Emirates and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioAro Inc., a biotechnology company at the forefront…

7 days ago

Tecan to host Analyst and Media Conference with Capital Markets Update on March 16, 2026

Männedorf, Switzerland, February 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference…

7 days ago

Hassan Spine & Sports Medicine Rebrands as NefraHealth

New Identity Reflects Patient-First Philosophy, Practice Growth Board-Certified Spine Surgeon Joins Growing Central Jersey Practice OLD BRIDGE, N.J., Feb. 10,…

7 days ago

Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article…

1 week ago

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet in the treatment of canine mast cell tumors

PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR…

1 week ago

Carterra Launches Industrys First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization

Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional and AI-based drug discoveryEnables primary screening with high-resolution…

1 week ago